Skip to main content
. Author manuscript; available in PMC: 2021 May 15.
Published in final edited form as: Clin Cancer Res. 2020 Sep 17;26(22):5860–5868. doi: 10.1158/1078-0432.CCR-20-2276

Figure 2:

Figure 2:

The figure represents duration (months) of response for each responder among 17 pathologically evaluable patients: 8 CRs, 3 PRs and 3 SDs. Five patients developed progressive disease during the follow-up: * Indicates progressive disease without developing invasive cancer (3 cases) and ** indicates progressive disease with developing invasive cancer (2 cases).